ClinicalTrials.gg

Program

GIA632

A development code.

In Novartis's pipeline, IL-15 mAb. Its studies are mostly in Vitiligo · Lichen Planus · Dermatitis, Atopic, led by Novartis.

Furthest: phase 2, since Oct 22, 20253 company-led studies, 3 open or runningNext primary completion: May 17, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novartis33 open or runningphase 2since Oct 22, 2025Oct 22, 2025May 17, 2027phase 2 · NCT07220577
  • Named in Novartis’s own pipeline as GIA632, phase 2, as of Nov 16, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 22, 2025First study: phase 2 study in Dermatitis, AtopicFirst studyNCT07220577 · 34 enrolled · United States, Bulgaria, Canada and more
  2. Feb 18, 2026Phase 2 study in VitiligoNCT07431177 · 210 planned · United States, Argentina, Australia and more
  3. Aug 17, 2026Phase 2 study in Lichen PlanusNCT07775924 · 259 planned · United States, Australia, Canada and more

Ahead

  1. May 17, 2027Primary completion: phase 2 study in Dermatitis, AtopicNCT07220577
  2. Jun 6, 2028Primary completion: phase 2 study in VitiligoNCT07431177
  3. Nov 22, 2028Primary completion: phase 2 study in Lichen PlanusNCT07775924

TargetBeta

“IL-15 mAb”the company's pipeline, read by Claude · source

Other programs on IL15

ProgramCompanyFurthest phaseStudies
nogapendekin alfa inbakiceptruleImmunityBiophase 345
efserakefusp alfaJiangsu HengRui Medicinephase 36
belacabnagene franleucelrulenkarta-incphase 23
SPGL008rule3SBiophase 23
Daxokafusp AlfaSanofiphase 22

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07775924Lichen Planus · United States, Australia, Canada and more2RecruitingNov 22, 2028259
NCT07431177Vitiligo · United States, Argentina, Australia and more2RecruitingJun 6, 2028210
NCT07220577Dermatitis, Atopic · United States, Bulgaria, Canada and more2Active, not recruitingMay 17, 202734

How it is read

Names in the registry

  • “GIA632”, 3 entries

Codes read as this program: GIA632.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.